RxDoctor Payments Data

Sadiq Ahmed, MD

Nephrology · Lexington, KYNPI 1912920679

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,600 of the $16,892 with a category attached, or 74.6%. Aurinia Pharma U.S., Inc. accounts for 87.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $16,476 and has fallen 99.1% since, to $150 in 2025. Among nephrology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,892in general payments, 2019–2025

Across 16 payments — averaging $1055.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$15K
  • AstraZeneca$2K
  • Otsuka America Pharmaceutical, Inc.$150
  • Mallinckrodt Enterprises LLC$147
$122,818in research payments, 2019–2025

Across 7 payments — averaging $17,545 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$123K

What the payments were for

  • Speaking & faculty fees$12,60075%
  • Travel & lodging$3,26519%
  • Food & beverage$1,0276%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,892 in reported general payments places this provider in the 95th percentile of 165 nephrology providers in Kentucky.

See all nephrology providers in Kentucky

Medicare billing

Part B allowed, 2024
$102,839
Medicare patients
191
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa37$36,540
LokelmaSodium Zirconium Cyclosilicate13$13,686
FarxigaDapagliflozin Propanediol16$13,174
Cinacalcet Hcl16$2,193
Nifedipine ErNifedipine47$1,975
Sevelamer Carbonate33$1,868
Clonidine11$1,436
Calcium Acetate14$1,395
Bumetanide27$1,118
Mycophenolate Mofetil11$1,057
Valsartan29$701
Allopurinol62$684
Midodrine Hcl11$674
Calcitriol44$443
Doxazosin Mesylate35$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$1,906$26,86029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 nephrology providers in Kentucky.

Other nephrology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →